Literature DB >> 32388913

Beyond skin deep: addressing comorbidities in psoriasis.

Tom Kovitwanichkanont1, Alvin H Chong1,2, Peter Foley1,2.   

Abstract

Psoriasis is a chronic inflammatory disease that is commonly encountered in primary care and is associated with significant morbidity that extends beyond the skin manifestations. Psoriasis is associated with an elevated risk of psoriatic arthritis, cardiovascular disease, obesity, insulin resistance, mental health disorders, certain types of malignancy, inflammatory bowel disease and other immune-related disorders, and hepatic and renal disease. Enhanced recognition of these comorbidities may lead to earlier diagnosis and potentially better overall health outcomes. Psoriatic nail involvement, severe skin disease and obesity are associated with a greater risk of psoriatic arthritis. Individuals with psoriasis should be routinely screened for psoriatic arthritis to allow for early intervention to improve long term prognosis. Life expectancy is reduced in people with psoriasis due to a variety of causes, with cardiovascular disease and malignancy being the most common aetiologies. Psoriasis affects several factors that contribute to worsened quality of life and increased risk of depression and anxiety. Effective therapies are now available that have been shown to concurrently improve skin disease, quality of life and psychiatric symptoms. As the concordance between psychosocial impact and objective disease severity does not always correlate, it is essential to tailor management strategies specifically to the needs of each individual. Cigarette smoking and excess alcohol consumption are among the most important modifiable risk factors that increase the likelihood of psoriasis development and severity of skin disease. This provides a compelling rationale for smoking cessation and limiting alcohol intake in people with psoriasis beyond their traditional harmful health consequences.
© 2020 AMPCo Pty Ltd.

Entities:  

Keywords:  Comorbidities; Immunosuppression; Primary care; Psoriasis; Skin diseases

Year:  2020        PMID: 32388913     DOI: 10.5694/mja2.50591

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  9 in total

Review 1.  Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis.

Authors:  Yan Wang; Jinxin Zang; Chen Liu; Zhongrui Yan; Dongmei Shi
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

2.  Should Mammography Be a Prerequisite Prior to Initiation of Biological Agents in Patients With Psoriasis?

Authors:  Funda Tamer; Ayla Gulekon
Journal:  Dermatol Pract Concept       Date:  2022-04-01

3.  Effect of cognitive behavioral therapy on anxiety and depression in patients with psoriasis: A protocol for systematic review and meta-analysis.

Authors:  Chuan Tan; Jianmei Jiang; Xiaoling Deng; Wei Xiang; Tingting Hu
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

4.  The risk of organ-based comorbidities in psoriasis: a systematic review and meta-analysis.

Authors:  Xuemei Tang; Ling Chen
Journal:  An Bras Dermatol       Date:  2022-07-15       Impact factor: 2.113

Review 5.  Cytokine Modulators in Plaque Psoriasis - A Review of Current and Prospective Biologic Therapeutic Approaches.

Authors:  Marisa L Strychalski; Henry S Brown; Stephanie C Bishop
Journal:  JAAD Int       Date:  2022-08-27

Review 6.  Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yue Feng; Baosen Zhou; Zhen Wang; Guijuan Xu; Lili Wang; Tingting Zhang; Yanping Zhang
Journal:  Int J Clin Pract       Date:  2022-09-21       Impact factor: 3.149

Review 7.  The Association Between Psoriasis and Cardiovascular Diseases.

Authors:  Ahmed Zwain; Mohanad Aldiwani; Hussein Taqi
Journal:  Eur Cardiol       Date:  2021-05-13

Review 8.  Cardiovascular comorbidities in psoriasis (Review).

Authors:  Daciana Elena Branisteanu; Alin Codrut Nicolescu; Daniel Constantin Branisteanu; Catalina Ioana Branisteanu; Andreea Corina Dragoi; Camelia Margareta Bogdanici; Mihaela Paula Toader; Andreea Lorena Tucaliuc; Andreea Dimitriu; Doru Daogaru; Ruxandra Angela Pirvulescu; Elena Andrese Porumb
Journal:  Exp Ther Med       Date:  2021-12-17       Impact factor: 2.447

9.  MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients.

Authors:  Hui Shen; Dan Wang; Mengyun Zhan; Hanping Ding; Hongbo Zhao
Journal:  J Clin Lab Anal       Date:  2021-12-24       Impact factor: 2.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.